Breast cancer drug rejected for nhs despite doubling destruction of tumours

Breast cancer drug rejected for nhs despite doubling destruction of tumours Women who took Perjeta were 40 per cent more likely to be disease-free after three years but the drug will not be available on the NHS following the decision by NICE. The Daily Mail